Roche Enters Definitive Merger Agreement To Acquire AI-Driven Digital Pathology Company PathAI For $750M Upfront And Up To $300M In Additional Milestone Payments
هوفمان-لا روش
هوفمان-لا روش ADR
ROCHE HOLDINGS AG
ROCHE HOLDINGS AG RHHBF | 0.00 | |
ROCHE HOLDINGS AG RHHBY | 0.00 | |
ROCHE HOLDINGS AG RHHVF | 0.00 |
- PathAI's best-in-class Image Management System (IMS) with advanced AI analysis and workflow capabilities will complement Roche's digital pathology portfolio to drive laboratory efficiency
- Combining Roche's strong position in companion diagnostics and PathAI's advanced AI platform helps accelerate clinical therapy development, foster the discovery of new biomarkers and create novel diagnostic tools
- These integrated capabilities will accelerate the shift from broad intervention toward personalised healthcare for patients